Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Autism Spectrum Disorder Therapeutics Market: By Disease Type: Autistic Disorder, Asperger’s Syndrome, Others; By Treatment Type; By Age Group; By Distribution Channel; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Autism Spectrum Disorder Therapeutics Market Outlook
The global autism spectrum disorder therapeutics market reached a value of about USD 3.33 billion in 2021. The market is further expected to grow at a CAGR of 6.7% in the forecast period of 2022-2027 to reach a value of approximately USD 4.64 billion by 2027.
Increasing Demand for Communication and Behavioural Therapies to Augment the Market Growth of ASD Therapeutics
Based on treatment type, the communication and behavioural therapies segment is expected to account for a significant share in the autism spectrum disorder therapeutics market. There is no cure for ASD, however, certain behavioural therapies can help reduce and manage problematic symptoms. Behavioural and speech language therapies aid in developing the patient’s social skills. Applied Behaviour Analysis (ABA) helps children with ASD learn how to communicate and play while diminishing troublesome behaviours. Research has shown that long term behavioural therapies has positively impacted children as well as adults with ASD.
The North American Region to Hold Substantial Share in the Market for Autism Spectrum Disorder Therapeutics
North America is expected to hold a significant share of the autism spectrum disorder therapeutics market during the forecast period, supported by increased number of ASD cases in the region. In 2021, the U.S. Food and Drug Administration authorised the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD). The region is also characterised by research and development in the field of ASD which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the USA, supports research focussed on the treatment and outcomes of autism spectrum disorder and related disorders.
Market Segmentation
Autism spectrum disorder (ASD) is a neurological development disability characterised with conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. ASD can begin at infancy and last throughout adulthood through a person’s life. ASD can be diagnosed based on behavioural patterns. ASD treatments are focussed on reducing the factors that interfere with people’s orderly functioning. Some of the drugs prescribed by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
By disease type, the market is divided into:
- Autistic Disorder
- Asperger’s Syndrome
- Pervasive Developmental Disorder (PDD)
- Others
Based on treatment type, the market can be segmented into:
- Communication and Behavioural Therapies
- Applied Behaviour Analysis (ABA)
- Speech and Language Therapy
- Occupational Therapy
- Others
- Drug Therapies
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
The market is bifurcated based on age group into:
- Child
- Adult
On the basis of distribution channel, the market can be divided into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Increasing Number of Pipeline Drugs and Investment in Research and Development for the Treatment of ASD Expected to Propel Market Growth
The forecast period is expected to witness the development of drugs to treat ASD. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the autism spectrum disorder therapeutics market during the forecast period. In 2022, STALICLA, a Swiss clinical stage biotech company announced the completion of the phase 1b trials for STP1. The trials allow the application of the company’s precision medicine discovery platform in ASD.
Over the forecast period, the rising number of ASD patients and the increasing awareness regarding the disease along with rising governmental initiatives is expected to encourage research in this area. Further, rapid technological advancements in medicine are expected to favour the market growth during the forecast period. Moreover, the adoption of behavioural therapies to overcome the communication gap in such patients is expected to further aid the market growth.
Key Players in the Global Market for Autism Spectrum Disorder Therapeutics
The report gives a detailed analysis of the following key players in the global autism spectrum disorder therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Neurim Pharmaceuticals, Inc.
- Q BioMed Inc.
- Hopebridge, LLC
- Yamo Pharmaceuticals LLC
- Curemark, LLC
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Region
7 Industry Opportunities and Challenges
8 Global Autism Spectrum Disorder Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Autism Spectrum Disorder Therapeutics Historical Market (2017-2021)
8.3 Global Autism Spectrum Disorder Therapeutics Market Forecast (2022-2027)
8.4 Global Autism Spectrum Disorder Therapeutics Market by Disease Type
8.4.1 Autistic Disorder
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Asperger’s Syndrome
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Pervasive Developmental Disorder (PDD)
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Autism Spectrum Disorder Therapeutics Market by Treatment Type
8.5.1 Communication and Behavioural Therapies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.1.4 Breakup by Type
8.5.1.4.1 Applied Behavior Analysis (ABA)
8.5.1.4.2 Speech and Language Therapy
8.5.1.4.3 Occupational Therapy
8.5.1.4.4 Others
8.5.2 Drug Therapies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.2.4 Breakup by Type
8.5.2.4.1 Antipsychotic Drugs
8.5.2.4.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
8.5.2.4.3 Stimulants
8.5.2.4.4 Sleep Medications
8.5.2.4.5 Others
8.6 Global Autism Spectrum Disorder Therapeutics Market by Age Group
8.6.1 Child
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Adult
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.7 Global Autism Spectrum Disorder Therapeutics Market by Distribution Channel
8.7.1 Hospital Pharmacies
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2017-2021)
8.7.1.3 Forecast Trend (2022-2027)
8.7.2 Retail Pharmacies
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2017-2021)
8.7.2.3 Forecast Trend (2022-2027)
8.7.3 Online Pharmacies
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2017-2021)
8.7.3.3 Forecast Trend (2022-2027)
8.8 Global Autism Spectrum Disorder Therapeutics Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Neurim Pharmaceuticals, Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Q BioMed Inc.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Hopebridge, LLC
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Yamo Pharmaceuticals LLC
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Curemark, LLC
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Autism Spectrum Disorder Therapeutics Market: Key Industry Highlights, 2017 and 2027
2. Global Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Disease Type (USD Billion), 2017-2021
3. Global Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Disease Type (USD Billion), 2022-2027
4. Global Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Treatment Type (USD Billion), 2017-2021
5. Global Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Treatment Type (USD Billion), 2022-2027
6. Global Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Distribution Channel (USD Billion), 2017-2021
7. Global Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Distribution Channel (USD Billion), 2022-2027
8. Global Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Autism Spectrum Disorder Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Autism Spectrum Disorder Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Autism Spectrum Disorder Therapeutics Market Structure.
Key Questions Answered in the Report
In 2021, the global autism spectrum disorder therapeutics market attained a value of nearly USD 3.33 billion.
The market is projected to grow at a CAGR of 6.7% between 2022 and 2027.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach about USD 4.64 billion by 2027.
The major drivers of the industry, such as the rising occurrences of ASD, increasing research and development aided by the government and industrial players, growing pipeline of ASD drugs, and rising focus on behavioural therapies, are expected to aid the market growth.
The key market trends include the increasing research and development to produce ASD drugs and rising awareness regarding ASD and its treatment.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The disease types covered in the report include autistic disorder, Asperger’s syndrome, and pervasive developmental disorder (PDD), among others.
The market is divided, based on treatment type, into communication and behavioural therapies and drug therapies.
The age groups considered in the market report include child and adult.
The various distribution channels in the market are hospital pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are Neurim Pharmaceuticals, Inc., Q BioMed Inc., Hopebridge, LLC, Yamo Pharmaceuticals LLC, and Curemark, LLC, among others.
Analyst Review
The global autism spectrum disorder therapeutics market attained a value of about USD 3.33 billion in 2021, driven by the rising research and development projects fostered by the government and market players. Aided by the growing focus on behavioural therapies, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 6.7%. The market is projected to reach nearly USD 4.64 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the market. By disease types, the market is segmented into autistic disorder, Asperger’s syndrome, and pervasive developmental disorder (PDD), among others. Based on treatment type, the market is segmented into communication and behavioural therapies, and drug therapies. The market, by age group, is bifurcated into child and adult. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The major regional markets for autism spectrum disorder therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Neurim Pharmaceuticals, Inc., Q BioMed Inc., Hopebridge, LLC, Yamo Pharmaceuticals LLC, and Curemark, LLC, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer...
The global hepatic disease treatment market attained a value of nearly USD 21.97 billion, driven by the rise in the prevalence of liver diseases. Aided by the increasing alcohol consumption and growin...
The global glaucoma therapeutics market attained a value of USD 7.24 billion in 2021, driven by the rising prevalence of glaucoma worldwide. Aided by the favourable reimbursement policies and growing ...
The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeli...
The global Duchenne muscular dystrophy (DMD) treatment market attained a value of USD 1.15 million in 2021, driven by the introduction of novel drugs and therapies. Aided by the increased DMD awarenes...
NEWSLETTER